Subscribe today to receive notice of our latest thought leadership, articles, and updates.
Insights
Clinical Connection
Clinical impact on workers' compensation and auto no-fault
Our latest white papers
Caring for workers affected by climate change
Climate change poses significant risks to the workforce. In our recent white paper, we explore the health challenges workers face, and how Optum programs and teams work together to address an injured worker’s varied and often codependent needs.
Read moreObesity in the workforce and GLP-1 medications
Breakthroughs in GLP-1 medications offer substantial health benefits for overweight injured workers. But clinical considerations and regulatory requirements can make authorization decisions more difficult. Our clinical team and policy experts are ready to help you navigate the evolving GLP-1 landscape while also focusing on best-in-class managed care strategies for your injured workers.
Read moreRecent updates
|
October 12, 2023 · Clinical Team
The 3Q 2023 Brand-Generic Pipeline update Read more... |
|
|
September 20, 2023 · Clinical Team
Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more... |
|
|
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more... |
|
|
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more... |
|
|
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more... |
|
|
July 18, 2023 · Clinical Team
The 2Q 2023 Brand-Generic Pipeline update Read more... |
|
|
July 06, 2023 · Clinical Team
Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more... |
|
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
Page 2 of 4